Entrada Therapeutics, Inc.
TRDANASDAQHealthcare● Active
$6.59
+$0.33(+5.19%)
Market Cap$255633756
P/E Ratio—
52W High$16.45
52W Low$4.93
Entrada Therapeutics, Inc. (TRDA) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · TRDA · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($143.75M) | $65.63M | ($6.68M) | ($94.62M) | ($51.16M) |
| Depreciation & Amort. | $0.42M | $3.77M | $2.84M | $1.90M | $1.12M |
| Stock-Based Comp. | $19.61M | $17.91M | $13.11M | $9.89M | $2.53M |
| Change in Working Capital | ($4.80M) | ($118.85M) | $136.31M | ($11.11M) | ($3.42M) |
| Net Cash from Operations | ($128.51M) | ($41.56M) | $139.80M | ($93.79M) | ($50.86M) |
| Investing Activities | |||||
| Capital Expenditure | ($1.04M) | ($3.16M) | ($5.61M) | ($2.89M) | ($4.58M) |
| Purchases of Investments | ($141.61M) | ($437.72M) | ($407.21M) | ($221.98M) | $0.00M |
| Sales of Investments | $259.46M | $413.08M | $274.43M | $76.21M | $0.00M |
| Net Cash from Investing | $116.81M | ($27.80M) | ($138.40M) | ($148.65M) | ($4.58M) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Cash from Financing | $0.89M | $102.96M | $21.04M | $0.48M | $307.46M |
| Free Cash Flow | |||||
| Free Cash Flow | ($129.55M) | ($44.72M) | $134.19M | ($96.67M) | ($55.44M) |
| FCF Margin %(computed) | -509.63% | -21.21% | 104.01% | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more Entrada Therapeutics, Inc. data
About Entrada Therapeutics, Inc. (TRDA) Cash Flow Statement
Entrada Therapeutics, Inc. generated operating cash flow of ($0.13B) and free cash flow of ($0.13B) for 2025 — a FCF margin of -509.63%. Capital expenditure was ($0.00B).
Frequently asked questions
TRDA · 4 questionsEntrada Therapeutics, Inc. generated free cash flow of ($0.13B) for 2025, down 189.7% year-over-year.
TRDA free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10